Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine

Coronavirus disease 2019 (COVID-19) booster vaccination is being comprehensively evaluated globally due to waning immunity and the emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Therefore, this study aimed to evaluate antibody responses in individuals vaccina...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Jira Chansaenroj, Nungruthai Suntronwong, Sitthichai Kanokudom, Suvichada Assawakosri, Ritthideach Yorsaeng, Preeyaporn Vichaiwattana, Sirapa Klinfueng, Lakana Wongsrisang, Donchida Srimuan, Thaksaporn Thatsanatorn, Thanunrat Thongmee, Chompoonut Auphimai, Pornjarim Nilyanimit, Nasamon Wanlapakorn, Natthinee Sudhinaraset, Yong Poovorawan
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	MDPI AG 2022-07-01
سلاسل:	Vaccines
الموضوعات:	third dose inactivated vaccine BBIBP-CorV viral vector vaccine mRNA vaccine
الوصول للمادة أونلاين:	https://www.mdpi.com/2076-393X/10/7/1071
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!